Elevation Point Wealth Partners LLC Invests $1.16 Million in IQVIA Holdings Inc. $IQV

Elevation Point Wealth Partners LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 5,986 shares of the medical research company’s stock, valued at approximately $1,157,000.

Several other large investors also recently modified their holdings of the stock. BlackRock Inc. purchased a new position in IQVIA in the second quarter valued at approximately $2,811,292,000. Boston Partners bought a new position in IQVIA during the third quarter worth about $676,698,000. Norges Bank purchased a new position in IQVIA in the 4th quarter valued at approximately $497,445,000. Victory Capital Management Inc. lifted its position in shares of IQVIA by 2,628.1% during the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after acquiring an additional 1,614,063 shares in the last quarter. Finally, Orbis Allan Gray Ltd boosted its holdings in shares of IQVIA by 96.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after acquiring an additional 933,554 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $260.17 on Monday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $42.82 billion, a price-to-earnings ratio of 32.28, a PEG ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $260.40. The firm’s 50-day moving average is $213.32 and its 200 day moving average is $187.21.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same period last year, the company earned $2.81 earnings per share. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Insider Activity at IQVIA

In related news, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 12,913 shares of company stock worth $3,098,793. Insiders own 1.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IQV. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. HSBC reaffirmed a “buy” rating and issued a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. BMO Capital Markets lifted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.